CN101468048A - Spikenard volatile oil and use of composition containing spikenard volatile oil in pharmacy - Google Patents
Spikenard volatile oil and use of composition containing spikenard volatile oil in pharmacy Download PDFInfo
- Publication number
- CN101468048A CN101468048A CNA2007101648079A CN200710164807A CN101468048A CN 101468048 A CN101468048 A CN 101468048A CN A2007101648079 A CNA2007101648079 A CN A2007101648079A CN 200710164807 A CN200710164807 A CN 200710164807A CN 101468048 A CN101468048 A CN 101468048A
- Authority
- CN
- China
- Prior art keywords
- volatile oil
- radix
- rhizoma nardostachyos
- compositions
- nardostachyos volatile
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a volatile oil of Nardostachys chinensis Batal and combination comprising the volatile oil and new use thereof in pharmacy, wherein the volatile oil treats or prevents arrhythmia of human and other animals. The volatile oil of Nardostachys chinensis Batal plays the role of inhibition on rat cardiac myocytes sodium ion channel with very wide therapeutic window and very high safety. Epicardial local infiltration and airway inhalation administration all can prolong the effective refractory period of rat cardiac muscle.
Description
Affiliated technical field
The present invention relates to the new purposes of Radix et Rhizoma Nardostachyos volatile oil in pharmacy, also relate to the new purposes of compositions in pharmacy that contains Radix et Rhizoma Nardostachyos volatile oil, this medicine is used for the treatment of or prevents to comprise people's animal arrhythmia; Also relate to this medicine or its compositions by lung, nasal administration and oral administration.
Background technology
Arrhythmia is the one of the main reasons that causes various deaths from heart disease, and especially at heart failure, when myocardial ischemia or myocardial infarction, ARR incidence rate, case fatality rate are higher.But at present the total effective percentage of antiarrhythmic drug only has 30%-60% (Zhou Jiang, Zhao Fei. WENXIN KELI treatment arrhythmia clinical observation on the therapeutic effect. Chinese Medicine, 2006,1 (6): 342～343).Up to now, all arrhythmia Western medicine exist arrhythmogenic effect simultaneously again at antiarrhythmic, be that the arrhythmia Western medicine has brought out new in therapeutic process or increased the weight of original arrhythmia, its incidence rate is on average about 13%, and the arrhythmia that medicine inspires can show as all ARR types.This serious adverse all can cause at all kinds of anti-arrhythmics (referring to the classification of Western medicine anti-arrhythmic).Its generation and age, sex, arteria coronaria pathological changes, clinical manifestation, pharmacokinetic parameters etc. all do not have definite relation (Fang Wenxian. the clinical practice of arrhythmia Chinese medicine. Chinese clinician, 2001,29 (4): 52).
Chinese medicine and pharmacy is the traditional characteristics medical science of China.It is reported that the late result of arrhythmia Chinese medicine is better than Western medicine, possible mechanism is: Chinese medicine has the characteristics of tangible a plurality of ion channel target spot effect.Generally, the Western medicine molecular weight is less, ion channel had stronger retardation, and do not have an effect that ion channel is regulated, and the Chinese medicine molecular weight is bigger, ion channel is not had stronger effect, but its many target spots that have action characteristic makes it may act on different ion channels, produce regulating action the ion channel function disorder.
Radix Et Rhizoma Nardostachyos (Nardostachys chinensis) has another name called fragrant pine, is the dry root and rhizome of Valerianaceae plant Radix Et Rhizoma Nardostachyos (Nardostachys chinensisBatal) or spoon Ye Gansong (Nardostachys jatamansi DC).The exsiccant root and rhizome of Radix Et Rhizoma Nardostachyos can be used as medicine, its abnormal smells from the patient fragrance, and acrid in the mouth, sweet, warm in nature has regulating QI to relieve pain, the function of relieving stagnation and activating the spleen.The clinical practice in ancient times is in stagnation of QI in spleen and stomach, abdominal distention; Also can be used for curing toothache etc.People such as Ma Chuangeng (Ma Chuangeng, Xiang Siyuan etc. the experimentation of the antiarrhythmic effect of Radix Et Rhizoma Nardostachyos ethanol extract. Anhui medical college journal, 1980,15 (4): 9) find that the ethanol extract intravenous administration has certain antiarrhythmic effect, but do not report the antiarrhythmic effect of volatile oil up to now.
Summary of the invention
Technical problem to be solved by this invention is to find a kind of effective site of Chinese medicine to be used for the treatment of arrhythmia.
The invention provides following technical scheme for this reason.
Radix Et Rhizoma Nardostachyos (Nardostachys chinensis) volatile oil and contain the purposes of compositions in pharmacy of Radix et Rhizoma Nardostachyos volatile oil, this medicine is used for the treatment of or prevents to comprise people's animal arrhythmia.Described Radix Et Rhizoma Nardostachyos is the dry root and rhizome for Valerianaceae plant Radix Et Rhizoma Nardostachyos (Nardostachys chinensis Batal) or spoon Ye Gansong (Nardostachys jatamansi DC).Described Radix et Rhizoma Nardostachyos volatile oil adopts the preparation of vapor distillation method.Radix Et Rhizoma Nardostachyos is pulverized or chopping, and the certain hour or do not soak of being soaked in water is inserted boiler, feed atmospheric steam or pressure (hydraulic) water steam, preferred pressure (hydraulic) water steam can reduce distillation time, distilled 2-200 hour, preferred 6-24 hour, condensation contained oil vapour, and preferred condensation temperature is less than 60 ℃, oil-water separation, oil slightly, thick oil adds anhydrous sodium sulfate or additive method dehydration, filter Radix et Rhizoma Nardostachyos volatile oil (quintessence oil).Should be yellow, yellow green, green or brown transparency liquid.
Described Radix et Rhizoma Nardostachyos volatile oil, comprise calamenene (Rhizoma Acori Calami alkene, Calarene), △
1 (10)-aristolenone-2 and Radix Et Rhizoma Nardostachyos alcohol (Jatamansinol).Because the complexity of Chinese medicinal components, Radix et Rhizoma Nardostachyos volatile oil also comprise following principal component and principal component not.Eucalyptole (Eucalyptol), australene (α-Pinene), nopinene (β-Pinene), β-Fructus Canarii albi alkene (β-Maaliene), aristolone (Aristolene), 1a, 2,3,4,4a, 5,6, the hot hydrogen-1,1 of 7b-, 4,7-tetramethyl-1H propane azulene, 4-(2,6,6,-trimethyl-1-thiacyclohexane alkene-1)-the 3-.DELTA.3-2-butenone, aromadendrane (Aromadendrane), cubebene diene (Carinane), Herba Apii graveolentis diene-3,7 (Selina-3.7-diene), spathulenol (Spathulenol), eucalyptus globulus terpene alcohol (Globulol), β-caryophyllene (β-caryophyllen), 1,2,3,4,5,6,7, the hot hydrogen-1 of 8-, 4-dimethyl-7-(1-methyl ethylidene)-Flos Chrysanthemi cyclenes, patchouli alcohol (Patchouli alchol), △
1 (10)-aristolenone-2 (△
1 (10)-Aristolenone-2), debilone (Debilone), jatamansone (Nardostachone, 1,8,9,10-tetradehydrouristolan-2-one), AI3-36122 (Nonadecane).
The described compositions that contains Radix et Rhizoma Nardostachyos volatile oil also comprises additives, and additives comprise solvent or cosolvent and/or antioxidant and/or surfactant.Described solvent or cosolvent are selected from water, ethanol, propanol, isopropyl alcohol, propylene glycol, glycerol, Polyethylene Glycol (PEG) 400, dimethyl sulfoxide (DMSO), oleic acid, described antioxidant is selected from fat-soluble antioxidant and water solublity antioxidant, and fat-soluble antioxidant is selected from propyl gallate, to hydroxyl tert-butyl group methoxybenzene (BHA), toluene di-tert-butyl phenol (BHT), lecithin, vitamin E, fragrant, tert-butyl hydroquinone (tertiary butylated hydroquinone) or claim tertiarybutylhydroquinone (Tertiary butylhydroquinone) repeatedly.Water soluble antioxidant is selected from vitamin C, sodium sulfite, sodium sulfite, sodium pyrosulfite, cysteine hydrochloride.Above-mentioned composition forms the solution of homogeneous, perhaps heterogenetic emulsion or microemulsion.Liquid atomizes through manually exerting pressure and is the drop of certain particle diameter, by nose or mouthful suction pulmonary, performance drug effect; Also can directly spray and cause nasal membrane, by nasal mucosa medicine administration, be necessary to add some penetrating agents this moment, preferably has better safe penetrating agent and comprise, azone, thiophene ketone, cholic acid, cholate etc.
The described compositions that contains Radix et Rhizoma Nardostachyos volatile oil that comprises additives also comprises propellant, and propellant is selected from one or more of fluorochloroparaffins (Freon), hydrofluoroalkane (HFA), propane, normal butane, iso-butane, carbon dioxide or nitrogen.Hydrofluoroalkane is selected from HFA 227 (1,1,1,2,3,3, the 3-heptafluoro-propane), HFA134a (1,1,1,2 ,-tetrafluoroethane), and its common name is respectively Apaflurane (Apaflurane) Norflurane (Norflurane).Because fluorochloroparaffins is to the destruction of ozone layer, existing relevant international convention bans use of fluorochloroparaffins (freon), therefore preferred non-dichlorodifluoromethan hydro carbons propellant.The effect of above-mentioned propellant is, relies on high pressure (liquefaction) gas in being enclosed in jar to make the pastille fluid composition be atomized into the drop of suitable particle diameter, can be accurate to reach pulmonary, brings into play drug effect.
The described compositions that contains Radix et Rhizoma Nardostachyos volatile oil is divided in the packaging container, makes aerosol or spray, by nose or lung administration, perhaps is injected into oral mucosa or skin surface transdermal administration.This container preferably has proportional valve, can fix every spray amount.
The described compositions that contains Radix et Rhizoma Nardostachyos volatile oil is characterized in that also comprising oil-soluble or water-soluble base, and described substrate fusing point is higher than 40 ℃, makes compositions at room temperature be solid state.Can make drop pill or other preparations, can be by sublingual administration or oral administration performance drug effect, preferred sublingual administration.Oil-soluble substrate is selected from draws together stearic acid, glyceryl monostearate, stearyl alcohol etc., and water-soluble base is selected from suitable molecular weight polyethylene glycol (PEG), as PEG2000, and PEG4000, PEG6000.Preferred water-soluble base.
Description of drawings
Fig. 1 clamp voltage when-80mV Radix Et Rhizoma Nardostachyos to the influence of myocardial cell inward electric current, the A. contrast; B. administration (Radix et Rhizoma Nardostachyos volatile oil test solution (1:20K)) is after 8 minutes; C. eluting; D. inward electric current was mapped to the time.Clamp voltage when depolarization stimulates when reaching 0mV cationic channel open, when using Radix et Rhizoma Nardostachyos volatile oil 1:20K, suppresses inward electric current when-80mV, this figure shows after the administration 8 minutes, and the inhibition of inward electric current reaches the highest.Behind the short-term eluting, inward electric current has slight rise.
Fig. 2 clamp voltage when-100mV Radix Et Rhizoma Nardostachyos to the influence of myocardial cell inward electric current, the A. contrast; B. administration Radix et Rhizoma Nardostachyos volatile oil test solution (1:20K); C. administration Radix et Rhizoma Nardostachyos volatile oil test solution (1:1K); D. inward electric current was mapped to the time.Clamp voltage reaches 0mV at-100mV when depolarization stimulates, and during concentration 1:20K, inward electric current and the no significant change of contrast just obviously suppress inward electric current when having only concentration to reach 1:1K (68g/L).This figure shows after the administration 1 minute, and the inhibition of inward electric current reaches the highest.
Two kinds of administering modes of Fig. 3 comparison are put ERP in each observing time.
Two kinds of administering modes of Fig. 4 comparison are put ERP/RR ratio in each observing time.
The specific embodiment
The preparation of embodiment 1 Radix et Rhizoma Nardostachyos volatile oil
Get the Radix Et Rhizoma Nardostachyos 1000g after the pulverizing, insert in the distilling apparatus, feed steam atmospheric distillation 6 hours, condensation contains oil vapour, and oil-water separation gets slightly oil, adds slightly oil of dried over sodium sulfate, filter Radix et Rhizoma Nardostachyos volatile oil 14.7g.Be shaped as the light green color transparent oily liquid, have fragrant and sweet abnormal smells from the patient.Density 0.952g/ml.
1. materials and methods
1.1 Radix et Rhizoma Nardostachyos volatile oil test solution: embodiment 1 gained Radix et Rhizoma Nardostachyos volatile oil 1.0 grams with the dimethyl sulfoxine dissolving, are added the normal saline standardize solution and are diluted to 1000ml, get Radix et Rhizoma Nardostachyos volatile oil test solution (1:1k), be equivalent to crude drug 68g/L.Radix et Rhizoma Nardostachyos volatile oil test solution (1:1k) dilution is got Radix et Rhizoma Nardostachyos volatile oil test solution (1:20k) for 20 times, be equivalent to crude drug 3.4g/L.
1.2 rat myocardial cell separation method: 8 of rats, body weight 200-300 gram, male and female are regardless of, lumbar injection 1000 units (1ml) heparin, the anesthesia of 15 minutes pneumoretroperitoneums injection 25-50mg (1ml) barbital sodium is opened breast rapidly and is cored, under 37 ℃ of constant temperature oxygen supply conditions in the Langendorff perfusion device perfusion, at first about 2～3 minutes with the normal Zinciodati Comp solution perfusion of 50ml, to remove its blood.Change no calcium liquid (MITRA/MORAD liquid) perfusion 5min then into, the same liquid of reuse has added collagenase, protease, the Digestive system of bovine serum albumin enzyme (BSA:Bovine Serum Albumin). circulation perfusion 10～15min, take off heart and cut off the atrium, carefully ventricle is cut into small pieces, temperature is incubated and vibration gently in MITRA/MORAD liquid, per 5～10min pours out serum and adds fresh MITRA/MORAD liquid, and slowly progressively increase Ca2+ until reaching 1.8mM, to reach gradually the effect of calcium again at every turn.3～5 times so repeatedly, isolated cells is at room temperature preserved after one hour and can be used.Or sedimentation cell was stored in 36 ℃ for using on the thin slice in little year.
1.3 full cell patch pincers record
1.3.1 the instrument and equipment that the patch-clamp record uses: patch clamp amplifier Axon/USA (Axopatch 200Bmplifier/pClamp9/Digidata pack1322A), accurate narishige SD/USA (MX7600/R MotorizedManipulator/MC 1000e Controller/Amplifier headstage mount), the fluorescence inverted microscope, 03-D type glass microelectrode draws instrument, MPS multichannel fast trace medicine system, vibration isolators, heart Langendorff perfusion device, the glass electrode pipe draws the instrument two step method through microelectrode and draws the electrode that electrode is drawn into most advanced and sophisticated 1～1.5 μ m, electrode charges interior liquid, and the entry impedance is 1～1.5M Ω.
1.3.2 patch-clamp logging program and method: the digital control constant temperature groove according to the difference of command potential, is distinguished measuring N a+ ion channel current under the voltage clamp pattern.Inhale in several cell-preservation liquids or the perfusion groove with dropper with year thin slice adding 2 of having cell, be placed on the inverted microscope workbench,, select flow liner clear with containing 100% saturated oxygen extracellular fluid with the perfusion device perfusion, the no granule in surface, shrinkage-free cell is as experimental subject.Make eletrode tip shift to cell surface, carry out sealing-in again,, compensate fast electric capacity and inhale the broken cell film to form full cell record pattern, regulate the compensation of slow capacitance compensation and series resistance to reduce instantaneous charging or discharging current and command potential error when impedance reaches more than the 1G Ω.Patch clamp amplifier links to each other with computer, and signal granting and collection are finished and are stored in the hard disk by software, for measuring and analyzing and use.
1.3.3 patch-clamp recording solution and reagent: normal tyrode's solution composition: NaCl 140mM; KCl 5.4mM; CaCl2 1.8mM; MgCl2 0.5mM; HEPES 5.0mM; Dextrose 5.5mM; NaH2PO4 0.4mM; PH transfers to 7.40 with NaOH.No calcium tyrode's solution (MITRA/MORAD does not add CaCl2 in the normal tyrode's solution); NaCl 135mM; KCl 5.4mM; MgCl2 1.0Mm; HEPES 10mM; Detrose 11mM; NaH2PO4 0.33mM; PH transfers to 7.30 with NaOH.Record external solution (External Solution): NaCl 25mM; MgCl2 1.2mM; HEPES 20mM; D-glucose11mM; CsCl 5mM; CoCl2 1.0mM; Tetramethylammonium chloride 115mM.Record internal solution (Internal Solution): CsF 145mM; NaF 5.6mM; HEPES 5mM; Transfer PH to 7.2 ± 0.02 with CsOH 1M.
2. result
Discover that the variable concentrations Radix et Rhizoma Nardostachyos volatile oil has the influence of different sodium-ion channels to rat myocardial cell under different clamp voltages, concentration 1:20K (being equivalent to crude drug 3.4g/L) only clamp voltage when-80mV, tangible retardation is arranged, administration after 8 minutes inward electric current suppress to reach the highest.And clamp voltage is when-100mV, and this concentration fails to cause the significant change of inward electric current.And concentration reaches 1:1K and presents tangible inward electric current when (being equivalent to crude drug 68g/L) and suppress, and less than 1 minute, it is the highest that the inhibition of inward electric current promptly reaches after the administration, sees Fig. 1, Fig. 2.
Above-mentioned experimental result shows that Radix et Rhizoma Nardostachyos volatile oil just directly relates to the refractory stage variation of cardiac muscular tissue to the Different Effects of rat myocardial cell cationic channel under different clamp voltages, thereby brings into play its antiarrhythmic effect.Wherein above-mentioned clamp voltage adapts at the voltage of-80mV and arrhythmia cell, and clamp voltage adapts at the voltage of-100mV and normal myocardium cell, therefore also show Radix et Rhizoma Nardostachyos volatile oil have non-constant width the treatment window, in concentration is that 1:1K (be equivalent to valid density 20 times) Shi Caihui influences normal cell, has very high safety.
1. materials and methods: healthy male Wistar rat (250 ± 50g) totally 50 are divided into medication group (n=40) and matched group (n=10).The medication group all gives the Radix et Rhizoma Nardostachyos volatile oil test solution (1:20K) among the embodiment 2 (quite crude drug 3.4g/L).The medication component is visceral pericardium local infiltration (n=20) and air flue inhalation group (n=20), and matched group is given the Radix et Rhizoma Nardostachyos volatile oil solvent.Visceral pericardium local infiltration administering mode is for dripping medicinal liquid 0.2ml to the visceral pericardium mode, air flue inhalation mode (is equivalent to contain volatile oil 10ug for dripping medicinal liquid 0.2ml, or be equivalent to crude drug 0.68mg) adsorb to cotton balls, as for the side pipe in the tee T, tee T one termination respirator, other end trachea intubate, the Radix et Rhizoma Nardostachyos volatile oil that volatilizes from cotton balls is along with respirator is moved into rat pulmonary.Before each group is divided into medication by administration time, after the medication 15,30,45,60min five time periods experimentize and observe.3% pentobarbital sodium is anaesthetized through rat abdominal cavity by 30mg/kg, and tracheal intubation exposes heart.
With Franz bipolar recording electrode sutured in the left ventricular apex visceral pericardium, the bipolar stimulation electrode then places the nearly coronary sulcus adventitia of free ventricular wall place, ventricular muscles produces propagable action potential, and the S1S2 interval of this moment is decided to be effective refractory period (ERP), press usual way mensuration ERP.Calculated correction value ERP/RR (RR is a heart rate).
Dual contrast is taked in experiment, i.e. self and matched group contrast before and after the medication are to eliminate individual variation.Experimental data all adopts mean ± standard deviation, and (x ± s) expression, each parameter is relatively used paired t-test before and after every group of medication, relatively adopts the t check of two sample means between group, finishes statistical procedures by the SPSS statistical software.
The result:
1. the administration of visceral pericardium local infiltration is to the influence of ERP: after the administration of visceral pericardium local infiltration 15,30,45,60min, ERP is 120.83 ± 7.93,124.17 ± 6.69,125.83 ± 12.40 respectively, 100.83 ± 9.00ms, respectively with medication before 66.67 ± 4.98ms and corresponding time matched group 68.0 ± 4.47,66.0 ± 5.48,68.0 ± 4.47 thereof, more all there were significant differences for 66.0 ± 5.48ms (p＜0.01), 15,30, ERP relatively (p〉0.05) between the 45min, compare with 60min ERP respectively that all there were significant differences (p＜0.01 Fig. 3).
2. air flue inhalation group is to the influence of ERP: after the administration 15,30,45,60min, ERP is 123.00 ± 6.75,127.00 ± 10.59,128.00 ± 11.35 respectively, 97.00 ± 12.52ms, ERP relatively (p〉0.05) respectively and before the medication after 64.00 ± 5.16ms and corresponding time matched group 64.0 ± 5.48,66.0 ± 5.48,68.0 ± 4.47 thereof, 64.0 ± 5.48ms relatively there were significant differences (p＜0.01) medication 15,30, between 45min compares with 60min ERP respectively that all there were significant differences (p＜0.01 Fig. 3).
3. visceral pericardium local infiltration, air flue inhalation group are to the influence of ERP/RR ratio: identical with the effect to ERP, the corresponding matched group with each of ERP/RR ratio compares that there were significant differences (p＜0.01 Fig. 4) after the medication.
4. observe relatively no difference of science of statistics between two kinds of administering modes (p〉0.05 Fig. 3) with ERP, but with the ERP/RR odds ratio than both, there is significant difference (p＜0.05 Fig. 4) in the influence owing to having eliminated heart rate between two kinds of administering modes.
Clinical general commonly used oral and vein gives antiarrhythmic drug, and clinical do not have volatile antiarrhythmic drug so far.Because Radix et Rhizoma Nardostachyos volatile oil is a kind of volatile material, be easy to from sucking and the infiltration administration, arrhythmia is paroxysmal often, the oral drugs drug action is slow, and intravenously administrable needs more to be carried out in hospital, and atomizing inhalation drug effect is rapid, half-life is shorter, side effect is little, carries and convenient, is convenient to first aid.For the effectiveness of clear and definite Radix et Rhizoma Nardostachyos volatile oil different way of administration, take visceral pericardium local infiltration and air flue inhalation mode in this experiment.
Relatively all 15 to 45min more steady, drug effect weakens gradually behind the 45min to the prolongation effect of ERP and ERP/RR ratio each time period in the group after the experimental result prompting medication, and it is rapid that this effect trend meets the volatile medicine onset, and characteristic rapidly disappears also.The result can obviously prolong the effective refractory period of ventricular muscles after showing the Radix et Rhizoma Nardostachyos volatile oil medication, and the prolongation of effective refractory period can make some anticipatory premature beats therefore be blocked, and can also block reentrant pathway, reaches the effect of anti-tachy-arrhythmia.
This experimental result compares two kinds of administering modes with the ERP evaluation does not have significant difference, and with after the ERP/RR ratio, then shows between two kinds of administering modes to exist significant difference.This result illustrates that on the one hand ERP/RR ratio reflects the influence of Radix et Rhizoma Nardostachyos volatile oil to ERP comparatively accurately, and also explanation sucks this medicine on the other hand, because medicine is delivered into pulmonary rapidly, pulmonary's blood capillary is abundant, compared with the administration of visceral pericardium local infiltration, blood drug level is higher, and drug effect is better.The proof Radix et Rhizoma Nardostachyos volatile oil is effectively a kind of and administering mode rapidly from the inhalation route administration.
Embodiment is used for the aerosol prescription that pulmonary sucks for 4 one kinds
The component recipe quantity
Radix et Rhizoma Nardostachyos volatile oil 1.0g
DMSO 0.2g
Water 1000ml
HFA?227 400g
Make 1000 bottles
Claims (8)
1. Radix et Rhizoma Nardostachyos volatile oil and contain the purposes of compositions in pharmacy of Radix et Rhizoma Nardostachyos volatile oil, this medicine is used for the treatment of or prevents to comprise people's animal arrhythmia.
2. Radix et Rhizoma Nardostachyos volatile oil according to claim 1 is characterized in that, adopts the preparation of vapor distillation method.
3. Radix et Rhizoma Nardostachyos volatile oil according to claim 1 is characterized in that, comprises calamenene, △
1 (10)-aristolenone-2 and Radix Et Rhizoma Nardostachyos alcohol.
4. the compositions that contains Radix et Rhizoma Nardostachyos volatile oil according to claim 1 is characterized in that, comprises that also additives, additives comprise solvent or cosolvent and/or antioxidant and/or surfactant.
5. the compositions that contains Radix et Rhizoma Nardostachyos volatile oil according to claim 4 is characterized in that, comprises that also propellant, propellant are selected from one or more of fluorochloroparaffins, hydrofluoroalkane, propane, normal butane, iso-butane, carbon dioxide or nitrogen.
6. the compositions that contains Radix et Rhizoma Nardostachyos volatile oil according to claim 4 is characterized in that compositions is divided in the packaging container, sprays or inhalation by nasal cavity or oral cavity, perhaps is injected into oral mucosa or skin surface transdermal administration.
7. the compositions that contains Radix et Rhizoma Nardostachyos volatile oil according to claim 1 is characterized in that also comprising oil-soluble or water-soluble base, and described substrate fusing point is higher than 40 ℃, makes compositions at room temperature be solid state.
8. the compositions that contains Radix et Rhizoma Nardostachyos volatile oil according to claim 7 is characterized in that, compositions is by sublingual administration or oral administration.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2007101648079A CN101468048A (en) | 2007-12-24 | 2007-12-24 | Spikenard volatile oil and use of composition containing spikenard volatile oil in pharmacy |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2007101648079A CN101468048A (en) | 2007-12-24 | 2007-12-24 | Spikenard volatile oil and use of composition containing spikenard volatile oil in pharmacy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101468048A true CN101468048A (en) | 2009-07-01 |
Family
ID=40826009
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2007101648079A Pending CN101468048A (en) | 2007-12-24 | 2007-12-24 | Spikenard volatile oil and use of composition containing spikenard volatile oil in pharmacy |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101468048A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102492554A (en) * | 2011-12-13 | 2012-06-13 | 向权 | Method for extracting essential oil by taking nardostachys chinensis as raw material |
| CN105153072A (en) * | 2015-09-23 | 2015-12-16 | 天津中医药大学 | Kanshone C and preparation method and application thereof |
| WO2018084336A1 (en) * | 2016-11-04 | 2018-05-11 | 주식회사한국전통의학연구소 | Pharmaceutical composition for prevention or treatment of liver cancer and health functional food |
-
2007
- 2007-12-24 CN CNA2007101648079A patent/CN101468048A/en active Pending
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102492554A (en) * | 2011-12-13 | 2012-06-13 | 向权 | Method for extracting essential oil by taking nardostachys chinensis as raw material |
| CN102492554B (en) * | 2011-12-13 | 2015-09-16 | 向权 | A kind of method taking rhizoma nardostachyos as raw material and extract essential oil |
| CN105153072A (en) * | 2015-09-23 | 2015-12-16 | 天津中医药大学 | Kanshone C and preparation method and application thereof |
| CN105153072B (en) * | 2015-09-23 | 2018-06-29 | 天津中医药大学 | Nardosinone C and preparation method and application |
| WO2018084336A1 (en) * | 2016-11-04 | 2018-05-11 | 주식회사한국전통의학연구소 | Pharmaceutical composition for prevention or treatment of liver cancer and health functional food |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU777789B2 (en) | Liquid composition to be vaporized for inhibiting increase in blood sugar level, vaporizer for the same and use of the same | |
| El Tahir et al. | The respiratory effects of the volatile oil of the black seed (Nigella sativa) in guinea-pigs: elucidation of the mechanism (s) of action | |
| WO2007086493A1 (en) | Medicine for transnasal administration | |
| EA003405B1 (en) | Method and device for delivering an aerosolized active agent to the lungs of a human patient | |
| Riley et al. | Prolongation of the QT interval by volatile anesthetics in chronically instrumented dogs | |
| US20040258623A1 (en) | Insulin-containing oral spray and the preparation method thereof | |
| CN109771431A (en) | The new application of honokiol derivative | |
| CN101467968A (en) | Preparation for novel administration route of antiarrhythmic medicament | |
| CN101468048A (en) | Spikenard volatile oil and use of composition containing spikenard volatile oil in pharmacy | |
| CN107998110A (en) | Resveratrol is used to prepare treatment or alleviates the purposes of chronic inflammatory airway disease medicine | |
| JPH04149126A (en) | Pharmaceutical composition for transmucous administration | |
| WO2017124640A1 (en) | Alendronate sodium powder inhalation used for respiratory drug deliver and application thereof | |
| Park et al. | Differential effects of insufflated, subcutaneous, and intravenous growth hormone on bone growth, cognitive function, and NMDA receptor subunit expression | |
| CN101049485A (en) | Mulberry - ginger soft capsule for treating common cold, and preparation method | |
| Taylor et al. | Plasma catecholamine concentrations: The effects of infiltration with local analgesics and vasoconstrictors during nasal operations | |
| Tessarolo Silva et al. | Multimodal mechanisms and enhanced efficiency of atrial fibrillation cardioversion by pulmonary delivery of a novel flecainide formulation | |
| CN101468047A (en) | Solid composition by intranasal administration, preparation method and administration device thereof | |
| Hachenbero et al. | Cardiopulmonary effects of internal cardioverter/defibrillator implantation | |
| Pillai et al. | The effect of pulmonary-delivered insulin on blood glucose levels using two nebulizer systems | |
| Fergusson et al. | Nebulized salbutamol in life-threatening asthma: is IPPB necessary? | |
| Forman et al. | Acute myocardial infarct extension into a previously preserved subendocardial region at risk in dogs and patients. | |
| CN107669821B (en) | Application of Jinma Gantai preparation in preparation of medicines for treating ischemia-reperfusion injury and related diseases | |
| NZ519403A (en) | Use of insulin in a medicament to reduce weight gain in a diabetic patient who is using exogenous insulin to control blood sugar levels | |
| Collier | Pharmacology of DO. O-Dimethyl Tubocurarine Iodide | |
| CN112656794B (en) | Application of pyrroloquinoline quinone or salt thereof in preparation of medicines for preventing and treating prostatic hyperplasia and pharmaceutical composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Open date: 20090701 |